NASDAQ:IFRX - InflaRx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$34.75 +0.36 (+1.05 %)
(As of 05/21/2018 04:46 AM ET)
Previous Close$34.75
Today's Range$34.46 - $36.2350
52-Week Range$14.47 - $42.83
Volume81,574 shs
Average Volume80,907 shs
Market Capitalization$813.50 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About InflaRx (NASDAQ:IFRX)

InflaRx logoInflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IFRX
CUSIPN/A
Phone49-36-4150-8180

Debt

Debt-to-Equity RatioN/A
Current Ratio26.05
Quick Ratio26.05

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.77 per share
Price / Book6.02

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees17
Outstanding Shares23,410,000

InflaRx (NASDAQ:IFRX) Frequently Asked Questions

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) released its quarterly earnings results on Thursday, May, 17th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.06. View InflaRx's Earnings History.

When is InflaRx's next earnings date?

InflaRx is scheduled to release their next quarterly earnings announcement on Thursday, August, 16th 2018. View Earnings Estimates for InflaRx.

What price target have analysts set for IFRX?

4 brokers have issued twelve-month price targets for InflaRx's stock. Their forecasts range from $30.00 to $42.00. On average, they expect InflaRx's share price to reach $35.75 in the next twelve months. View Analyst Ratings for InflaRx.

Who are some of InflaRx's key competitors?

Who are InflaRx's key executives?

InflaRx's management team includes the folowing people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director
  • Prof. Renfeng Guo M.D., Co-Founder, Chief Scientific Officer & Exec. Director (Age 48)
  • Mr. Arnd Christ MBA, Chief Financial Officer (Age 52)
  • Dr. Maria Habel PH.D., Head of Preclinical R&D (Age 36)
  • Dr. Othmar Zenker M.D., Chief Medical Officer (Age 56)

When did InflaRx IPO?

(IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

When did the company's lock-up period expire?

InflaRx's lock-up period expired on Monday, May 7th. InflaRx had issued 6,667,000 shares in its public offering on November 8th. The total size of the offering was $100,005,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Has InflaRx been receiving favorable news coverage?

News headlines about IFRX stock have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. InflaRx earned a coverage optimism score of 0.15 on Accern's scale. They also gave news articles about the company an impact score of 46.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are InflaRx's major shareholders?

InflaRx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.88%), Redmile Group LLC (3.64%), Citadel Advisors LLC (0.57%), Artal Group S.A. (0.53%), Schwab Charles Investment Management Inc. (0.05%) and Northern Trust Corp (0.03%). View Institutional Ownership Trends for InflaRx.

Which major investors are selling InflaRx stock?

IFRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and Redmile Group LLC. View Insider Buying and Selling for InflaRx.

Which major investors are buying InflaRx stock?

IFRX stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Artal Group S.A., Schwab Charles Investment Management Inc., Northern Trust Corp and Barclays PLC. View Insider Buying and Selling for InflaRx.

How do I buy shares of InflaRx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $34.75.

How big of a company is InflaRx?

InflaRx has a market capitalization of $813.50 million. InflaRx employs 17 workers across the globe.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180.


MarketBeat Community Rating for InflaRx (IFRX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about InflaRx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

InflaRx (NASDAQ:IFRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for InflaRx in the last 12 months. Their average twelve-month price target is $35.75, suggesting that the stock has a possible upside of 2.88%. The high price target for IFRX is $42.00 and the low price target for IFRX is $30.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.75$34.25$33.00N/A
Price Target Upside: 2.88% upside18.76% upside45.05% upsideN/A

InflaRx (NASDAQ:IFRX) Consensus Price Target History

Price Target History for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Leerink SwannReiterated RatingOutperform$42.00LowView Rating Details
2/8/2018B. RileyInitiated CoverageBuy ➝ Buy$40.00LowView Rating Details
12/4/2017BMO Capital MarketsInitiated CoverageOutperform$31.00HighView Rating Details
12/4/2017JPMorgan ChaseInitiated CoverageOverweight$30.00HighView Rating Details
(Data available from 5/21/2016 forward)

Earnings

InflaRx (NASDAQ:IFRX) Earnings History and Estimates Chart

Earnings by Quarter for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.28 EPS
Next Year EPS Consensus Estimate: $-1.78 EPS

InflaRx (NASDAQ IFRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/16/2018        
5/17/2018Q1 2018($0.34)($0.40)$0.04 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

InflaRx (NASDAQ:IFRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

InflaRx (NASDAQ IFRX) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 42.79%
Insider Trading History for InflaRx (NASDAQ:IFRX)
Institutional Ownership by Quarter for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ IFRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

InflaRx (NASDAQ IFRX) News Headlines

Source:
DateHeadline
Inflarx NV (IFRX) PT Raised to $42 at Leerink PartnersInflarx NV (IFRX) PT Raised to $42 at Leerink Partners
www.streetinsider.com - May 19 at 9:34 AM
InflaRxs (IFRX) Outperform Rating Reaffirmed at Leerink SwannInflaRx's (IFRX) Outperform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - May 18 at 5:15 PM
InflaRx (IFRX) Posts Quarterly  Earnings Results, Misses Estimates By $0.10 EPSInflaRx (IFRX) Posts Quarterly Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - May 18 at 8:14 AM
InflaRx N.V. Reports First Quarter 2018 Financial & Operating ResultsInflaRx N.V. Reports First Quarter 2018 Financial & Operating Results
finance.yahoo.com - May 17 at 9:53 AM
Reader Inquiry: Is InflaRx A Buy On The Dip?Reader Inquiry: Is InflaRx A Buy On The Dip?
seekingalpha.com - May 13 at 10:05 AM
InflaRx prices stock offering at $34; shares down 3% premarketInflaRx prices stock offering at $34; shares down 3% premarket
seekingalpha.com - May 4 at 9:32 AM
InflaRx N.V. Announces Pricing of Primary and Secondary Offering of Common SharesInflaRx N.V. Announces Pricing of Primary and Secondary Offering of Common Shares
finance.yahoo.com - May 4 at 9:32 AM
Inflarx (IFRX) Rating Increased to Hold at ValuEngineInflarx (IFRX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 4 at 12:41 AM
InflaRx N.V. (IFRX) Reports Primary and Secondary Offerings of Common SharesInflaRx N.V. (IFRX) Reports Primary and Secondary Offerings of Common Shares
www.streetinsider.com - May 2 at 9:34 AM
InflaRx N.V. Announces Proposed Primary and Secondary Offerings of Common SharesInflaRx N.V. Announces Proposed Primary and Secondary Offerings of Common Shares
finance.yahoo.com - May 2 at 9:34 AM
Inflarx NV (IFRX) Receives Consensus Recommendation of "Buy" from AnalystsInflarx NV (IFRX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 2 at 3:34 AM
Inflarx NVs (IFRX) Lock-Up Period Set To End  on May 7thInflarx NV's (IFRX) Lock-Up Period Set To End on May 7th
www.americanbankingnews.com - April 30 at 1:18 AM
 Inflarx NV (IFRX) Given Average Recommendation of "Strong Buy" by Analysts Inflarx NV (IFRX) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - April 22 at 7:28 AM
Inflarx (IFRX) Downgraded to Sell at Zacks Investment ResearchInflarx (IFRX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 10:27 AM
Zacks: Inflarx NV (IFRX) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Inflarx NV (IFRX) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 7 at 9:42 AM
Inflarx (IFRX) Rating Reiterated by Leerink SwannInflarx (IFRX) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - April 2 at 8:39 AM
Zacks: Brokerages Expect Inflarx NV (IFRX) Will Announce Earnings of -$0.23 Per ShareZacks: Brokerages Expect Inflarx NV (IFRX) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 31 at 1:22 PM
InflaRx Full Year 2017 Financial & Operating ResultsInflaRx Full Year 2017 Financial & Operating Results
finance.yahoo.com - March 29 at 10:04 AM
Brokerages Expect Inflarx NV (IFRX) to Post ($0.23) Earnings Per ShareBrokerages Expect Inflarx NV (IFRX) to Post ($0.23) Earnings Per Share
www.americanbankingnews.com - March 23 at 1:32 AM
Blog Exposure - InflaRx Enrolled First Patient in Phase-IIb Trial of Lead Candidate IFX-1 in Hidradenitis SuppurativaBlog Exposure - InflaRx Enrolled First Patient in Phase-IIb Trial of Lead Candidate IFX-1 in Hidradenitis Suppurativa
finance.yahoo.com - March 12 at 10:37 AM
InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis SuppurativaInflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa
finance.yahoo.com - March 8 at 10:03 AM
Zacks: Inflarx NV (IFRX) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Inflarx NV (IFRX) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 8 at 3:28 AM
-$0.23 EPS Expected for Inflarx NV (IFRX) This Quarter-$0.23 EPS Expected for Inflarx NV (IFRX) This Quarter
www.americanbankingnews.com - February 25 at 11:58 AM
Analysts Expect Inflarx NV (IFRX) to Post ($0.23) EPSAnalysts Expect Inflarx NV (IFRX) to Post ($0.23) EPS
www.americanbankingnews.com - February 21 at 3:20 PM
Zacks: Inflarx NV (IFRX) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Inflarx NV (IFRX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 18 at 7:40 PM
Zacks: Inflarx NV (IFRX) Given $33.00 Average Target Price by AnalystsZacks: Inflarx NV (IFRX) Given $33.00 Average Target Price by Analysts
www.americanbankingnews.com - February 13 at 1:42 PM
Inflarx NV to Post FY2017 Earnings of ($0.74) Per Share, B. Riley Forecasts (IFRX)Inflarx NV to Post FY2017 Earnings of ($0.74) Per Share, B. Riley Forecasts (IFRX)
www.americanbankingnews.com - February 12 at 1:08 AM
Inflarx (IFRX) Receives New Coverage from Analysts at B. RileyInflarx (IFRX) Receives New Coverage from Analysts at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM
Zacks: Inflarx NV (IFRX) Given $33.00 Consensus Target Price by AnalystsZacks: Inflarx NV (IFRX) Given $33.00 Consensus Target Price by Analysts
www.americanbankingnews.com - February 10 at 3:28 PM
InflaRx Announces Appointment of Tony Gibney to Its Board of DirectorsInflaRx Announces Appointment of Tony Gibney to Its Board of Directors
finance.yahoo.com - February 6 at 9:01 AM
InflaRx Presents at Two Scientific Conferences in February, 2018InflaRx Presents at Two Scientific Conferences in February, 2018
finance.yahoo.com - February 1 at 4:33 PM
Breaking Down InflaRx NV’s (NASDAQ:IFRX) Ownership StructureBreaking Down InflaRx NV’s (NASDAQ:IFRX) Ownership Structure
finance.yahoo.com - January 23 at 4:13 PM
What Can We Expect for InflaRx NV (NASDAQ:IFRX) Moving Forward?What Can We Expect for InflaRx NV (NASDAQ:IFRX) Moving Forward?
finance.yahoo.com - January 15 at 6:27 PM
InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis SuppurativaInflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa
finance.yahoo.com - January 9 at 6:55 PM
InflaRx to Present at Upcoming Investor ConferencesInflaRx to Present at Upcoming Investor Conferences
finance.yahoo.com - January 4 at 6:30 PM
InflaRx NV (NASDAQ:IFRX): Are Analysts Bull Or Bear?InflaRx NV (NASDAQ:IFRX): Are Analysts Bull Or Bear?
finance.yahoo.com - January 4 at 8:11 AM
Inflarx NVs (IFRX) Quiet Period Set To End  on December 18thInflarx NV's (IFRX) Quiet Period Set To End on December 18th
www.americanbankingnews.com - December 11 at 1:08 AM
Inflarx (IFRX) Research Coverage Started at J P Morgan Chase & CoInflarx (IFRX) Research Coverage Started at J P Morgan Chase & Co
www.americanbankingnews.com - December 4 at 11:10 PM
Inflarx (IFRX) Earns Outperform Rating from Analysts at BMO Capital MarketsInflarx (IFRX) Earns Outperform Rating from Analysts at BMO Capital Markets
www.americanbankingnews.com - December 4 at 8:22 PM
Inflarx (IFRX) Now Covered by Leerink SwannInflarx (IFRX) Now Covered by Leerink Swann
www.americanbankingnews.com - December 4 at 7:24 AM
Fireman B.V. (IFRX) Plans to Raise $100 Million in November 8th IPOFireman B.V. (IFRX) Plans to Raise $100 Million in November 8th IPO
www.americanbankingnews.com - October 31 at 1:22 AM

SEC Filings

InflaRx (NASDAQ:IFRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

InflaRx (NASDAQ IFRX) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.